Kendall Park, NJ, United States of America

Shankaran Kothandaraman

This inventor holds 8 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., The Ohio State University. Active years: 2000-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shankaran Kothandaraman. Retrieved from https://idiyas.com/inventor/shankaran-kothandaraman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 2)

% Patents Active = 87.5

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 7.9

ph-index = 3

Forward Citations = 28(Granted Patents)

Location History:

Kendall Park, NJ (US) (2000 - 2010)
Plain City, OH (US) (2018 - 2022)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 1,577

The Ohio State University

patents

4. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11419951 - Peptide-based cancer imaging agents (2022-08-23),

2. 9969752 - Inhibitors of HIF prolyl hydroxylase (2018-05-15),

3. 7786305 - Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity (2010-08-31),

4. 7230008 - Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity (2007-06-12),

5. 7166614 - Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity (2007-01-23),

6. 6812234 - Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity (2004-11-02),

7. 6476054 - Cyclic amine modulators of chemokine receptor activity (2002-11-05),

8. 6140349 - Cyclic amine modulators of chemokine receptor activity (2000-10-31),

Title: Innovator Spotlight: Shankaran Kothandaraman

Introduction:

Shankaran Kothandaraman, a prolific inventor based in Kendall Park, NJ (US), has made significant contributions to the field of biomedical research with a total of 8 patents to his name. His groundbreaking work in developing peptide-based cancer imaging agents and inhibitors of HIF prolyl hydroxylase has garnered attention and praise in the scientific community.

Latest Patents:

Among his latest patents are two remarkable innovations: Peptide-based cancer imaging agents and Inhibitors of HIF prolyl hydroxylase. The former focuses on novel tumor-targeting peptides, while the latter involves compounds that inhibit HIF prolyl hydroxylase, enhancing the endogenous production of erythropoietin and treating conditions associated with anemia. These patents showcase Kothandaraman's commitment to advancing medical research and improving patient outcomes.

Career Highlights:

Kothandaraman has lent his expertise to esteemed companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His dedication to developing cutting-edge solutions for complex medical challenges has positioned him as a key player in the pharmaceutical industry.

Collaborations:

Throughout his career, Kothandaraman has collaborated with top professionals in the field, including coworkers like Sander G Mills and Richard Jiao. These collaborations have led to innovative projects and the successful development of groundbreaking technologies.

Conclusion:

In conclusion, Shankaran Kothandaraman's pioneering work in biomedical research has had a profound impact on the industry. His passion for innovation and his dedication to improving healthcare outcomes make him a standout inventor in the field. With a track record of impressive patents and collaborations with top industry experts, Kothandaraman continues to push the boundaries of what is possible in the world of medical science.

Profile summary based on public USPTO records.